The Clinical Outcomes of COVID-19 in Patients with Behçet’s Disease: A Series of 7 Cases and Brief Review of the Literature

Abstract

Conventional debates surrounding the treatment of coronavirus disease 2019 still continue in the literature. Colchicine is one of the recommended agents in the treatment of coronavirus disease 2019, but there are also studies giving negative opinions for the said agent. Some researchers suggest that those patients using colchicine have milder clinic symptoms. Behçet’s disease is a multisystemic disease with an uncertain etiopathogenesis that is characterized by chronic inflammatory vasculitis. Autoimmunity is believed to play a key role in the pathogenesis of Behçet’s disease. Immunomodulator, corticosteroid, and immunosuppressive drugs are used in its treatment. Seven Behçet’s patients with coronavirus disease 2019 were presented in this study, and the drugs used, prognosis, accompanying diseases, hospitalization, and complications were discussed in the light of the literature.

Epidemiological Profile of Bechcet’s Disease in Hospitalized Patients Infected With SARS-CoV-2 in Brazil: A Serial Case Report and a Literature Review

“…In this context, it is postulated that some treatments, such as the use of colchicine had no link with COVID-19 among those with BD [10,22]. In this context, it is postulated that some treatments, such as the use of colchicine had no link with COVID-19 among those with BD [10,22,32], except in one study that investigated 7 cases and concluded that the use of colchicine may be effective in the treatment of COVID-19 and in managing the severity of the clinical phenotype [33].…”

“…However, the authors also described a high frequency of pneumonia and thrombosis among the patients [32]. In contrast, a study published by Nas and collaborators (2022) investigated 7 cases and concluded that the use of colchicine may be effective in the treatment of COVID-19 and in managing the severity of the clinical phenotype [33]. Mehta and collaborators (2021) published a case report from a 54-year-old man with multiple pseudoaneurysms and COVID-19 that calls for attention to the challenges of diagnosing BD in patients with multiple symptoms [34].…”